AbbVie
ABBV
$192.45
Share price
-1.31%
Change (1 day)
13.02%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
AbbVie (ABBV) - Cash on Hand
Cash on Hand as of March 2025 : $5.17 Billion USD
According to AbbVie's latest financial reports the company has $5.17 Billion USD in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
AbbVie - Cash on Hand chart (from 2011 to 2025)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2024-12-31 | $5.55 B | -56.66% |
| 2023-12-31 | $12.81 B | 38.87% |
| 2022-12-31 | $9.22 B | -6.11% |
| 2021-12-31 | $9.83 B | 15.93% |
| 2020-12-31 | $8.47 B | -78.76% |
| 2019-12-31 | $39.92 B | 395.27% |
| 2018-12-31 | $8.06 B | -17.65% |
| 2017-12-31 | $9.78 B | 52.41% |
| 2016-12-31 | $6.42 B | -23.6% |
| 2015-12-31 | $8.40 B | 0.39% |
| 2014-12-31 | $8.37 B | -15.37% |
| 2013-12-31 | $9.89 B | 24.06% |
| 2012-12-31 | $7.97 B | 1121.44% |
| 2011-12-31 | $0.65 B | 5960.32% |
| 2010-12-31 | $10.77 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $17.31 B | 234.54% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $11.78 B | 127.63% | 🇺🇸 USA |
 Eli Lilly LLY | $3.22 B | -37.78% | 🇺🇸 USA |
 Amgen AMGN | $8.81 B | 70.21% | 🇺🇸 USA |
 Gilead Sciences GILD | $7.92 B | 53.13% | 🇺🇸 USA |
 Biogen BIIB | $2.59 B | -49.80% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $5.79 B | 11.96% | 🇬🇧 UK |
 AstraZeneca AZN | $5.39 B | 4.23% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | $0.94 B | -81.77% | 🇺🇸 USA |